Tirzepatide is FDA approved for type 2 diabetes and chronic weight management. Learn what the approval covers, dosing, safety, side effects, and more.
Tirzepatide is FDA approved for two brand-name prescription medicines: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The FDA approved Mounjaro in May 2022 and Zepbound in November 2023. Compounded or research-grade tirzepatide sold online is not FDA approved.
What “Tirzepatide FDA Approved” Actually Means
The FDA approves specific drug products, not molecules in general. That means a tirzepatide fda approval applies to a particular manufacturer, formulation, dose, and labeled use — not to every vial that contains tirzepatide.
If you are asking is tirzepatide fda approved, the answer is yes for the two Eli Lilly products below. It is no for compounded versions, gray-market vials, and “research use only” powders.
- Mounjaro — tirzepatide injection approved as an adjunct to diet and exercise to improve blood sugar in adults with type 2 diabetes.
- Zepbound — tirzepatide injection approved for chronic weight management in adults who meet specific BMI criteria.
FDA-Approved Tirzepatide Products at a Glance
| Brand name | FDA approval date | Approved use | How it is given |
|---|---|---|---|
| Mounjaro | May 13, 2022 | Type 2 diabetes in adults | Once-weekly injection |
| Zepbound | November 8, 2023 | Chronic weight management in adults | Once-weekly injection |
Both products use the same active ingredient, tirzepatide, a dual GIP and GLP-1 receptor agonist. The difference is the labeled indication, the dose escalation schedule, and the packaging.
The FDA later expanded Zepbound’s label to include moderate-to-severe obstructive sleep apnea in adults with obesity, based on trial data. That expansion is a good example of how an approval can grow as new evidence arrives.
What Conditions Is Tirzepatide Approved For?
Approval is tied to specific patient groups. Tirzepatide is not FDA approved for general cosmetic weight loss, for children, or for people who do not meet the labeled criteria.
Type 2 diabetes
Mounjaro is approved to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise. It is not approved as a first-line replacement for insulin in every situation, and it is not a cure for diabetes.
Chronic weight management
Zepbound is approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is intended for long-term use along with a reduced-calorie diet and increased physical activity.
Obstructive sleep apnea
Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. It is used with a reduced-calorie diet and increased physical activity.
Tirzepatide vs. Compounded Tirzepatide
Compounded tirzepatide is not FDA approved. Compounding pharmacies are regulated by state boards and by FDA outsourcing rules, but their products do not go through the same new-drug approval process as Mounjaro or Zepbound.
During the 2022–2024 shortage, some pharmacies made compounded tirzepatide. After the shortage ended, the FDA said compounding copies of tirzepatide was no longer permitted because an approved product was available. Enforcement has varied, but the legal and safety picture is clear: compounded tirzepatide is not an FDA-approved drug.
This matters because dosing errors, impurities, and unverified potency have been reported with compounded and gray-market peptides. If a product claims fda approval tirzepatide but is not Mounjaro or Zepbound, treat that claim skeptically.
Is Tirzepatide FDA Approved for Weight Loss?
Yes — but only under the Zepbound label and only for adults who meet the criteria. Zepbound is not approved for weight loss in the general sense, and it is not approved for people with a BMI below 27.
In clinical trials, adults taking tirzepatide lost more weight on average than those taking placebo, and many reached a 5% or greater reduction. Individual results vary, and the drug is meant to be used long term. Stopping the medication often leads to weight regain, which is why clinicians usually pair it with lifestyle changes and ongoing follow-up.
Safety, Side Effects, and Boxed Warnings
Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodents. The drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. These often improve as the dose stabilizes, but they can become serious if dehydration develops.
More serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and low blood sugar when used with insulin or sulfonylureas. Anyone considering tirzepatide should talk with a healthcare professional about their medical history, current medications, and pregnancy status.
Other Peptides and Their FDA Approval Status
People researching peptides often mix up approved prescription drugs with unapproved research chemicals. A common forum question is is aod-9604 fda approved, and the answer is no. Any aod-9604 fda approved claim on a vendor page should be viewed with caution.
The same is true for growth-hormone secretagogues. Searching is cjc-1295/ipamorelin fda-approved returns no FDA-approved drug listing, and cjc-1295 ipamorelin fda-approved products are not sold as legal prescription medicines in the United States.
| Peptide | FDA-approved? | Typical legal status |
|---|---|---|
| Tirzepatide (Mounjaro, Zepbound) | Yes, for labeled uses | Prescription only |
| AOD-9604 | No | Sold as a research chemical; not for human use |
| CJC-1295 / Ipamorelin | No | Not approved for human use |
These peptides are sometimes marketed with phrases borrowed from approved drugs to gain credibility. That is a marketing tactic, not a regulatory fact. The FDA approval tirzepatide received applies only to Mounjaro and Zepbound.
The Bottom Line
Tirzepatide is FDA approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea. Compounded tirzepatide and research peptides are not FDA approved.
If you want to use tirzepatide, the safest path is a prescription from a licensed clinician and a product from a verified pharmacy. Ask your healthcare professional whether the benefits outweigh the risks for your situation.
Frequently Asked Questions
Is tirzepatide FDA approved for weight loss?
Yes, but only under the Zepbound brand and only for adults who meet specific criteria. Zepbound is approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition. It is not approved for general cosmetic weight loss.
When did the FDA approve tirzepatide?
The FDA approved Mounjaro (tirzepatide) for type 2 diabetes on May 13, 2022. Zepbound (tirzepatide) was approved for chronic weight management on November 8, 2023. Zepbound later received an additional approval for obstructive sleep apnea in adults with obesity.
Is compounded tirzepatide FDA approved?
No. Compounded tirzepatide is not reviewed or approved by the FDA for safety, effectiveness, or quality. After the tirzepatide shortage ended, the FDA said compounding copies were no longer permitted because approved products were available. Only Mounjaro and Zepbound are FDA-approved tirzepatide products.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.